Archon, a Seattle, WA-based biotechnology firm offering computationally designed Antibody Cages (AbCs), raised $20M in Seed funding.
The spherical was led by Madrona Ventures with participation from DUMAC Inc., Sahsen Ventures, WRF Capital, Pack Ventures, Alexandria Enterprise Investments and Cornucopian Capital.
The corporate intends to make use of the funds to increase operations and its enterprise attain.
Led by CEO James Lazarovits, Archon is a biotechnology firm creating computationally designed proteins to unlock therapeutic targets that lie past the attain of present modalities and to raised deal with illness. It straight applies generative protein design to quickly manufacture Antibody Cages (AbCs), a brand new class of biologics with distinctive efficiency and differentiated biodistribution. AbCs combine the unparalleled binding affinity and specificity of antibodies into novel self-assembling nanostructures designed to beat essentially the most tough challenges in drug improvement.
FinSMEs
30/10/2024
